Allogeneic transplantation for recurrent or refractory non-Hodgkin's lymphoma with poor prognostic features after conditioning with thiotepa, busulfan, and cyclophosphamide: Experience in 44 consecutive patients

Biology of Blood and Marrow Transplantation

Volumn 3, Issue 3, 1997, Pages 150-156

  Van Besien, Koen ^a,b   Thall, Peter ^a   Korbling, Martin ^a   Pugh, William C ^a   Khouri, Issa ^a   Mehra, Rakesh ^a   Giralt, Sergio ^a   Anderlini, Paolo ^a   Amin, Kamal ^a   Mirza, Nadeem ^a   Seong, David ^a   Gajewski, James ^a   Hester, Jeane ^a   Andersson, Borje ^a   Cabanillas, Fernando ^a   Champlin, Richard ^a   Przepiorka, Donna ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Allogeneic transplantation; Blood stem cells; Lymphoma

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; THIOTEPA;

ADULT; ALLOTRANSPLANTATION; ARTICLE; BONE MARROW TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG COMBINATION; DRUG EFFECT; FEMALE; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MALE; MIDDLE AGED; MORTALITY; NONHODGKIN LYMPHOMA; PROGNOSIS; PROSPECTIVE STUDY; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; BONE MARROW TRANSPLANTATION; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DRUG THERAPY, COMBINATION; FEMALE; GRAFT SURVIVAL; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RECURRENCE; THIOTEPA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 0031201119     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649, 1991.
2. Ratanatharathorn V, Uberti J, Karanes C, Abella E, Lum LG, Momin F, Cummings G, Sensenbrenner LL: Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma. Blood 84:1050, 1994.
3. Van Besien KW, de Lima M, Giralt SA, Moore DFJ, Khouri I, Rondón G, Mehra R, Andersson B, Dyer C, Cleary K, Przepiorka D, Gajewski J, Champlin RE: Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effects. Bone Marrow Transplant 19:982, 1997.
4. Petersen FB, Appelbaum FR, Bigelow CL, Buckner CD, Clift RA, Sanders JE, Storb R, Sullivan KM, Weiden PL, Fefer A, Thomas ED: High-dose cytosine arabinoside, total body irradiation and marrow transplantation for advanced malignant lymphoma. Bone Marrow Transplant 4:483, 1989.
5. Przepiorka D, Nath R, Ippoliti C, Mehra R, Hagemeister F, Diener K, Dimopoulos M, Giralt S, Khouri I, Samuels B, van Besien K, Andersson B, Deisseroth AB, Luna M, Cabanillas F, Champlin R: A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma. Leuk Lymphoma 17:427, 1995.
6. Thall PF, Simon R, Estey EH: A new statistical strategy for monitoring safety and efficacy in single-arm clinical trials. J Clin Oncol 14:296, 1996.
7. Thall PF, Simon R, Estey EH: Bayesian sequential monitoring designs for single-arm clinical trials with multiple outcomes. Statistics in Medicine 14:357, 1995.
8. Przepiorka D, Ippoliti C, Giralt S, Van Besien KW, Mehra R, Deisseroth AB, Andersson B, Luna M, Cork A, Lee M, Estey E, Andreeff M, Champlin RE: A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic bone marrow transplantation. Bone Marrow Transplant 14:449, 1994.
9. The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer 49:2112, 1982.
10. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, Sonneveld P, Gisselbrecht C, Cahn J, Haroussean J, Coiffer B, Biron P, Mandelli F, Chauvin F: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540, 1995.
11. Korbling M, Przepiorka D, Huh YO, Engel H, Van Besien KW, Giralt S, Andersson B, Kleine HD, Seong D, Deisseroth AB, Andreef M, Champlin R: Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: potential advantage of blood over marrow allografts. Blood 85:1659, 1995.
12. dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease. Blood 86:2842, 1995.
13. Przepiorka D, Madden T, Ippoliti C, Estrov Z, Dimopoulos M: Dosing of thiotepa for myeloablative therapy. Cancer Chemother Pharmacol 37:155, 1995.
14. van Besien K, Przepiorka D, Mehra R, Giralt S, Khouri I, Gajewski J, Andersson B, Champlin RE: High-dose thiotepa, busulfan and cyclophosphamide for patients with hematologic malignancies and CNS involvement. J Clin Oncol 14:3036, 1996.
15. Ratanatharathorn V, Nash RA, Devine SM, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW, Nademanee AP, Antin JH, Karanes C, Avalos BR, Christiansen NP, Van der Jagt RH, Herzig RH, Litzow MR, Wolff SN, Longo WR, Petersen FB, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR: Phase III study comparing tacrolimus (Prograf, FK506) with cyclosporine for graft-versus-host-disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 88, Suppl 1:459a, 1996. [abstract]
16. Wingard J, Nash RA, Przepiorka D, Klein JL, Weisdorf DJ, Fay JW, Zhu J, Maher RM, Fitzsimmons WE, Ratanatharathorn V: Relationship of tacrolimus whole concentrations and efficacy and safety after HLA-identical sibling transplantation. Blood 88 Suppl 1:460a, 1996. [abstract]
17. Yee GC, Self SG, McGuire TR, Carlin J, Sanders JE, Deeg HJ: Serum cyclosporine concentrations and risk of acute graft-versus-host disease after allogeneic transplantation. N Engl J Med 319:65, 1988.
18. Przepiorka D, Shapiro S, Schwinghammer TL, Bloom EJ, Rosenfeld CS, Shadduck RK, Venkataramanan R: Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease. Bone Marrow Transplant 7:461, 1991.
19. Przepiorka D, Weisdorf D, Martin P, Klingemann H, Beatty P, Hows J, Thomas ED: Consensus conference on GVHD grading. Bone Marrow Transplant 15:825, 1995.
20. Przepiorka D, Ippoliti C, Panina A, Goodrich J, Giralt S, Van Besien KW, Mehra R, Deisseroth AB, Andersson B, Luna M, Tarrand JJ, Champlin RE: Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after t-cell depleted marrow transplantation. Bone Marrow Transplant 13:461, 1994.
21. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD: Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Int Med 118:173, 1993.
22. Masur H: Drug therapy: prevention and treatment of pneumocystis pneumonia. N Engl J Med 327:1853, 1992.
23. Przepiorka D, Selvaggi K, Rosenzweig PQ, Borochovitz D, Taylor D: Aerosolized pentamidine for prevention of Pneumocystis pneumonia after allogeneic marrow transplantation. Bone Marrow Transplant 7:324, 1991.
24. Tran HT, Ippoliti C, van Besien K, Anaissie EJ, Champlin RC: Aerosolized amphotericin-B in allogeneic transplant recipients for the prevention of fungal pneumonia. Proceedings of the Keystone Symposia 71, 1996. [abstract]
25. Bearman SI, Appelbaum FR, Buckner CD, Petersen FB, Fisher LD, Clift RA, Thomas ED: Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 6:1562, 1988.
26. Shimamoto Y, Pichyangkul S, Khan A: Enhancement of cell-mediated cytotoxicity by recombinant tumor necrosis factor (TNF). Proc Soc Exp Biol Med 189:310, 1988.
27. Cox DR: Regression models and life tables (with discussions). J Royal Statist Soc (Series B) 34:187, 1972.
28. Venables WN, Ripley BD: Modern applied statistics with S-plus. New York, Springer Verlag, 1994.
29. Pregibon D: Resistant fits for some commonly used logistic models with medical applications. Biometrics 38:485, 1982.
30. Therneau TM: A package for survival analysis in S. Mayo Foundation, 1994. [abstract]
31. de Lima M, van Besien K, Giralt SA, Khouri IF, Mehra R, Andersson B, Przepiorka D, Gajewski J, Champlin RE: Bone marrow transplantation after failure of autologous transplant for non-Hodgkin's lymphoma. Bone Marrow Transplant 19:121, 1997.
32. Van Besien KW, Mehra R, Khouri I, Giralt SA, Andersson B, Dimopoulos M, Przepiorka D, Gajewski J, Rodriguez A, Besa P, Deisseroth AB, Champlin R: Double intensification and allogeneic or autologous bone marrow transplantation for poor prognosis lymphoma. Blood 82 Suppl I:146a, 1993. [abstract]
33. Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg J, Fefer A, Hill R, Mortimer J, Neiman PE, Sanders JE, Singer J, Stewart P, Storb R, Thomas ED: Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol 5:1340, 1987.
34. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: a case-controlled analysis of the European Bone Marrow Transplant Group registry data. J Clin Oncol 10:1690, 1992.
35. Soiffer R, Neuberg D, Freedman AS, Alyea EP, Fisher DC, Bartlett-Pandite L, Gribben J, Schlossman RL, Freeman A, Anderson KC, Nadler LM, Ritz J: CD6 depleted allogeneic and syngeneic bone marrow transplantation for non-Hodgkin's lymphoma. Blood 88, Suppl 1:683a, 1996. [abstract]
36. van Besien K, Mehra R, Giralt SA, Kantarjian HM, Pugh WA, Khouri IF, Moon Y, Williams P, Andersson BS, Przepiorka D, McCarthy PL, Gajewski JL, Deisseroth AB, Cabanillas F, Champlin RE: Allogeneic bone marrow transplantation for poor prognosis lymphoma. Response, toxicity and survival depend on disease histology. Am J Med 100:299, 1996.
37. Neidhart JA, Kubica R, Stidley C, Pfile J, Clark D, Rinehart J: Multiple cycles of dose-intensive cyclophosphamide, etoposide, and cisplatinum (DICEP) produce durable responses in refractory non-Hodgkin's lymphoma. Cancer Invest 12:1, 1994.
38. Neidhart JA, Kohler W, Stidley C, Mangalik A, Plauche A, Anderson T, Quenzer RW, Rinehart JJ: Phase I study of repeated cycles of high-dose cyclophosphamide, etoposide, and cisplatin administered without bone marrow transplantation. J Clin Oncol 8:1728, 1990.
39. Przepiorka D, Anderlini P, Ippoliti C, Khouri I, Fietz T, Thall P, Mehra R, Giralt S, Gajewski J, Deisseroth A, Cleary K, Champlin R, van Besien K, Andersson B, Körbling M: Allogeneic blood stem cell transplantation in advanced hematologic malignancies. Bone Marrow Transplant 19:455, 1997.
40. Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Mehra R, Giralt S, Gajewski J, Fritsche H, Deisseroth A, Champlin R, van Besien K, Andersson B, Korbling M: Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplant 62:1806, 1996.
41. Mills W, Chopra R, McMillan A, Pearce R, Linch DC, Goldstone AH: BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 13:588, 1995.
42. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137, 1993.
43. Van Besien KW, Giralt S, Mehra R, Khouri I, Rodriguez A, Andersson B, Korbling M, Przepiorka D, Cabanillas F, Champlin R: High dose beam as conditioning for allogeneic transplantation in lymphoid malignancies. Blood 88 Suppl 1:618a, 1996. [abstract]
44. Przepiorka D, Ippoliti C, Khouri I, Anderlini P, Le Bherz D, Van Besien KW, Ueno N, Mehra R, Giralt S, Gajewski J, Fritsche H, Cleary K, Claxton D, Champlin R, Andersson B, Korbling M: Microdose methotrexate vs methylprednisolone in combination with tacrolimus for prevention of acute graft-vs-host disease (gvhd) after allogeneic blood stem cell transplantation. Blood 88 Suppl 1:418a, 1996. [abstract]